DocMorris goes European: new branding for marketplaces in Spain and France
11.2.2021 11:41:32 CET | news aktuell GmbH | Pressemelding
Heerlen/Barcelona, 11.02.2021 – DocMorris is taking the next step in implementing its new brand architecture on the way to becoming the European umbrella brand of the digital healthcare ecosystem of the Zur Rose Group. The successful launch of the new branding for the DocMorris pharmacy and the DocMorris+ healthcare platform in Germany marked just the beginning of a shift of paradigm to digital healthcare. This successful first step in Germany is now followed by PromoFarma, the leading brand for online pharmacy marketplaces in Spain, and DoctiPharma, the second biggest brand in France, who see their brand now linked to the DocMorris brand identity.
The new brand appearance of PromoFarma and DoctiPharma underlines its brand evolutions by using the green heart as a symbol for health. The varying shades of green for the heart represent the variety of current and future health solutions, which can be made even more personal and individual thanks to digitalisation. The light green “by DocMorris” descriptor confirms its link and shows both marketplaces are part of the European healthcare ecosystem.
DocMorris, best known in Germany, has been chosen by the Zur Rose Group as umbrella brand for its European healthcare ecosystem. The international success of the Christmas film “#Herzensangelegenheit” [a matter of the heart] emphasises the strength of the DocMorris brand and how the brand emotionally resonates with consumers across European markets. The cooperation with global healthcare company Novo Nordisk in Germany – with the intention to expand it across Europe – demonstrates how important it is to work with top-class partners in healthcare to bring the ecosystem to life under one single brand. Combining specialist knowledge from partners with consumer reach makes it possible to better enable people to manage their own health and improve their quality of life conveniently and flexibly. Gaining additional marketplace expertise in Spain and France within the healthcare ecosystem increases its attractiveness for consumers allowing for more product accessibility and faster time-to-market. With the ambition to expand further their product offering and providing additional digital services, PromoFarma and DoctiPharma will also benefit from the existing expertise under the DocMorris brand and many years of experience across the Zur Rose Group to make it even simpler for people to access healthcare.
On this basis, the DocMorris healthcare ecosystem will enable people all over Europe to manage their health in one click – safely and easily. The healthcare ecosystem will make it possible for all users, medical specialists, pharmacists and healthcare service providers to experience the vision of seamless and personal 360-degree health journeys.
The European DocMorris branding was developed with the famous international design agency Mucho of Barcelona, Spain.
Kontakter
eHealth ecosystem contact
Betül Susamis Unaran
Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com
Phone +41 79 834 41 40
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom

